- Home
- GLBZ vs BOLT Comparison
GLBZ vs BOLT Comparison
Compare GLBZ & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLBZ
- BOLT
- Stock Information
- Founded
- GLBZ 1949
- BOLT 2015
- Country
- GLBZ United States
- BOLT United States
- Employees
- GLBZ N/A
- BOLT N/A
- Industry
- GLBZ Major Banks
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- GLBZ Finance
- BOLT Health Care
- Exchange
- GLBZ Nasdaq
- BOLT Nasdaq
- Market Cap
- GLBZ 14.1M
- BOLT 16.8M
- IPO Year
- GLBZ N/A
- BOLT 2021
- Fundamental
- Price
- GLBZ $5.16
- BOLT $0.37
- Analyst Decision
- GLBZ
- BOLT Hold
- Analyst Count
- GLBZ 0
- BOLT 5
- Target Price
- GLBZ N/A
- BOLT $1.13
- AVG Volume (30 Days)
- GLBZ 8.7K
- BOLT 145.0K
- Earning Date
- GLBZ 04-29-2025
- BOLT 05-13-2025
- Dividend Yield
- GLBZ 1.87%
- BOLT N/A
- EPS Growth
- GLBZ N/A
- BOLT N/A
- EPS
- GLBZ N/A
- BOLT N/A
- Revenue
- GLBZ $11,254,000.00
- BOLT $7,690,000.00
- Revenue This Year
- GLBZ N/A
- BOLT N/A
- Revenue Next Year
- GLBZ N/A
- BOLT $77.45
- P/E Ratio
- GLBZ N/A
- BOLT N/A
- Revenue Growth
- GLBZ N/A
- BOLT N/A
- 52 Week Low
- GLBZ $3.37
- BOLT $0.30
- 52 Week High
- GLBZ $6.99
- BOLT $1.34
- Technical
- Relative Strength Index (RSI)
- GLBZ 51.27
- BOLT 48.52
- Support Level
- GLBZ $4.70
- BOLT $0.33
- Resistance Level
- GLBZ $5.59
- BOLT $0.39
- Average True Range (ATR)
- GLBZ 0.27
- BOLT 0.04
- MACD
- GLBZ 0.01
- BOLT 0.00
- Stochastic Oscillator
- GLBZ 46.46
- BOLT 66.06
About GLBZ Glen Burnie Bancorp
Glen Burnie Bancorp is a bank holding company for The Bank of Glen Burnie. It offers retail and commercial banking services such as checking, savings, loans, mobile banking, online banking, wire transfer, ACH services, debit cards, automated teller machines, and safe deposit boxes among others. The bank generates its revenue in the form of interest income. All of the revenues are earned within the United States.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.